About MukoCell
MukoCell is a Healthcare company based in Dortmund (Germany) founded in 2013. It operates as a developer of stem cell based therapy to reconstruct organs. Its focus areas include Life Sciences, Genitourinary Disorders, Drugs and Life Sciences Platforms and Tools. Its legal entity is MukoCell GmbH. Its competitors include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Founded in 2013 in Dortmund, Germany, the company operates in the biotechnology sector, where stem cell-based technologies are advanced to generate replacement tissues and reconstruct damaged organs. Focus is placed on regenerative medicine solutions, with a primary product applied in the treatment of urethral stenosis. Research and development efforts are centered on therapeutic applications for urological conditions, supporting clinical advancements in tissue engineering.
- Headquarters Dortmund, Germany
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website mukocell.com
- Social X Facebook
- Legal Name Mukocell Gmbh
- Latest Funding Round$59.38K (USD), Grant
Jul 2021
- InvestorsEuropean Union
& 1 more
Funding Insights of MukoCell
- Total Rounds 2
- Last Round Grant — $59,382
- First Round $2.15M
(Aug 2018)
- Investors Count 2
All 2 funding rounds of MukoCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $59,382 | Grant | – | – | |
| Aug 2018 | $2.15M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in MukoCell
MukoCell has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for MukoCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of MukoCell
3 dated milestones of MukoCell across 8 years, from founding to its latest funding, stage changes and deals.
- Founded MukoCell is founded.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Grant, of $59K.
Competitors of MukoCell
MukoCell has 10 listed competitors in our database, 9 of them funded. They include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of MukoCell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MukoCell
Websites that share an audience with MukoCell (mukocell.com).
Websites whose visitors overlap most with MukoCell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details | |
| facebook.com | 100% | 12.1B | #3 | View details | |
curos-urologie.de | curos-urologie.de | 98% | – | #2,058,832 | – |
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as MukoCell (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MukoCell
MukoCell was founded in 2013 and raised its 1st funding round 5 years after it was founded.
MukoCell is headquartered in Dortmund, Germany. It is registered at Dortmund, North Rhine-westphalia, Germany.
Founded in 2013 in Dortmund, Germany, the company operates in the biotechnology sector, where stem cell-based technologies are advanced to generate replacement tissues and reconstruct damaged organs. Focus is placed on regenerative medicine solutions, with a primary product applied in the treatment of urethral stenosis. Research and development efforts are centered on therapeutic applications for urological conditions, supporting clinical advancements in tissue engineering.
MukoCell's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
MukoCell has 2 investors. Key investors include European Union, and EIC Fund.
MukoCell operates through Mukocell Gmbh.